https://advisory.avalerehealth.com/insights/status-of-us-prescription-drug-importation-pathways
Patient Affordability and Access to Prescription Drugs As federal and state policymakers consider policies to lower drug costs, state drug importation has...
of usprescription drugavalere healthstatusimportation
https://advisory.avalerehealth.com/insights/updated-negotiation-icr-presents-new-industry-evidence-needs
Background The first round of Medicare drug price negotiation is concluding and maximum fair prices for the first 10 selected Part D drugs will be released by S
new industryavalere healthupdatednegotiationicr
https://avalerehealth.com/
Avalere Health is a global strategic partner for the healthcare industry. Learn how our advisory, medical, and marketing experts unite to reach every patient.
avalere healtheverypatientpossible
https://advisory.avalerehealth.com/insights/novel-antibiotic-use-is-low-even-for-complex-cases
Novel antibiotic development has been relatively stagnant for decades, despite critical unmet need and the development of antimicrobial resistance (AMR) around
novelantibioticuseloweven
https://advisory.avalerehealth.com/insights/obbba-and-medicare-negotiation-eligibility-considerations-for-manufacturers
The Medicare Drug Price Negotiation Program (MDPNP) excluded products with only indication(s) approved under a single orphan drug designation. The One Big Beaut
avalere healthobbbamedicarenegotiationeligibility